This company listing is no longer active
Avinger (AVGR) Stock Overview
A commercial-stage medical device company, designs, manufactures, and sells a suite of image-guided and catheter-based systems used by physicians to treat patients with peripheral artery disease (PAD) primarily in the United States and Germany. More details
| Snowflake Score | |
|---|---|
| Valuation | 2/6 |
| Future Growth | 2/6 |
| Past Performance | 0/6 |
| Financial Health | 3/6 |
| Dividends | 0/6 |
Rewards
Risk Analysis
+ 1 more risk
AVGR Community Fair Values
Create NarrativeSee what others think this stock is worth. Follow their fair value or set your own to get alerts.
Join community and earn perks
Avinger, Inc. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | US$0.47 |
| 52 Week High | US$4.92 |
| 52 Week Low | US$0.36 |
| Beta | 1.1 |
| 1 Month Change | -21.00% |
| 3 Month Change | -39.92% |
| 1 Year Change | -88.85% |
| 3 Year Change | -99.31% |
| 5 Year Change | -99.73% |
| Change since IPO | -100.00% |
Recent News & Updates
Recent updates
Shareholder Returns
| AVGR | US Medical Equipment | US Market | |
|---|---|---|---|
| 7D | 3.0% | -3.6% | -1.5% |
| 1Y | -88.8% | -15.8% | 13.3% |
Return vs Industry: AVGR underperformed the US Medical Equipment industry which returned 11.6% over the past year.
Return vs Market: AVGR underperformed the US Market which returned 23.7% over the past year.
Price Volatility
| AVGR volatility | |
|---|---|
| AVGR Average Weekly Movement | 49.7% |
| Medical Equipment Industry Average Movement | 8.2% |
| Market Average Movement | 6.9% |
| 10% most volatile stocks in US Market | 15.3% |
| 10% least volatile stocks in US Market | 2.9% |
Stable Share Price: AVGR's share price has been volatile over the past 3 months compared to the US market.
Volatility Over Time: AVGR's weekly volatility has increased from 27% to 50% over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2007 | 70 | n/a | avinger.com |
Avinger, Inc., a commercial-stage medical device company, designs, manufactures, and sells a suite of image-guided and catheter-based systems used by physicians to treat patients with peripheral artery disease (PAD) primarily in the United States and Germany. The company develops lumivascular platform that integrates optical coherence tomography visualization with interventional catheters to provide real-time intravascular imaging during the treatment portion of PAD procedures. Its lumivascular products comprise Lightbox imaging consoles; the Ocelot and Tigereye family of devices, which are designed to allow physicians to penetrate a total blockage in an artery; and Pantheris, an image-guided atherectomy device that allows physicians to precisely remove arterial plaque in PAD patients.
Avinger, Inc. Fundamentals Summary
| AVGR fundamental statistics | |
|---|---|
| Market cap | US$1.52m |
| Earnings (TTM) | -US$17.35m |
| Revenue (TTM) | US$7.26m |
Is AVGR overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| AVGR income statement (TTM) | |
|---|---|
| Revenue | US$7.26m |
| Cost of Revenue | US$5.74m |
| Gross Profit | US$1.52m |
| Other Expenses | US$18.87m |
| Earnings | -US$17.35m |
Last Reported Earnings
Sep 30, 2024
Next Earnings Date
n/a
| Earnings per share (EPS) | -5.43 |
| Gross Margin | 20.94% |
| Net Profit Margin | -238.96% |
| Debt/Equity Ratio | 107.6% |
How did AVGR perform over the long term?
See historical performance and comparisonCompany Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2025/02/19 04:16 |
| End of Day Share Price | 2025/02/14 00:00 |
| Earnings | 2024/09/30 |
| Annual Earnings | 2023/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* Example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.
Analyst Sources
Avinger, Inc. is covered by 9 analysts. 1 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Marc Wiesenberger | B. Riley Securities, Inc. |
| Sean Lavin | BTIG |
| Jason Mills | Canaccord Genuity |